
The U.S. Food and Drug Administration’s approval process for the controversial Alzheimer’s drug Aduhelm was “rife with irregularities,” despite lingering doubts about the power of the pricey medication to slow the disease down, a Congressional report released Thursday claims. Actions the agency took with Biogen, maker of Aduhelm, “raise serious concerns about FDA’s lapses in… read on > read on >